All In Biotech

Drug Trial Radar · NCT01785186

Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design

A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis

Last checked: Nov 19, 2026Latest source record: Sep 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

365

Actual

Start

Apr 2013

Primary completion

Sep 2014

Study completion Mar 2015

Sponsor

Lead sponsor
Michael HoelscherAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sequella, Inc.; European and Developing Countries Clinical Trials Partnership (EDCTP); German Federal Ministry of Education and Research; Medical Research Council; Radboud University Medical Center
First posted
Feb 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multiple-arm, multiple-stage (MAMS), phase 2, open label, randomized, controlled clinical trial that will compare the efficacy and safety of four experimental four drug regimens with a standard control regimen in patients with smear positive, pulmonary tuberculosis (TB). Patients will be randomly allocated to the control or one of the four experimental regimens in the ratio 2:1:1:1:1. Experimental regimens will be given for 12 weeks. Thereafter, participants in the experimental arms will receive continuation phase treatment for 14 weeks containing standard-dose rifampicin and isoniazid. All participants will receive 25 mg of vitamin B6 (pyridoxine) with every dose of INH to prevent INH-related neuropathy. Interim analyses will be conducted during the trial for efficacy, with the aim of identifying experimental arms that perform below a pre-specified efficacy threshold; these arms will then be stopped from further recruitment. Following the first scheduled interim analysis on March 3rd, the Trial Steering Committee (TSC) followed a recommendation of the independent data monitoring committee (IDMC) and has stopped the enrolment into two of the arms in the MAMS-TB trial: HRZQ and HR20ZQ, based on these arms not meeting the pre-specified gain in efficacy over control. Importantly, there was no safety concern that prompted stopping recruitment to these arms. They recommended that recruitment to arm 2 (HRZQ) and 3 (HR20ZQ) be terminated as there was insufficient evidence that these regimens could shorten treatment. Importantly, there was no evidence that either arm was inferior to standard treatment (the control arm) with regards to efficacy. There was, however, sufficient evidence that the other intervention arms HR35ZE and HR20ZM could shorten treatment to continue enrolling patients.

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • SQ109Drug

    SQ109 300 mg

  • RifampicinDrug

    Rifampicin 10 to 35 mg/kg

  • MoxifloxacinDrug

    Moxifloxacin 400mg

  • isoniazidDrug

    isoniazid 75 mg

  • pyrazinamideDrug

    pyrazinamide 400 mg

  • ethambutolDrug

    ethambutol 275 mg

  • pyridoxineDietary supplement

    pyridoxine 25 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sputum Culture Conversion (2 Negative Cultures) Using Liquid MediaTime frame: 0 - 12 weeks

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • TASK Applied Science

    Bellville, South Africa

  • University of Cape Town, Centre for Tuberculosis Research Innovation

    Cape Town, South Africa

  • Wits Health Consortium

    Johannesburg, South Africa

  • The Aurum Institute for Health Research

    Johannesburg, South Africa

  • Ifakara Health Institute

    Bagamoyo, Tanzania

  • NIMR - Mbeya Medical Research Programme

    Mbeya, Tanzania

  • Kilimanjaro Christian Medical Centre (KCMC) / Kilimanjaro Clinical Research Institute (KCRI) (with affiliated field sites such as Kibong'oto National Tuberculosis Hospital Same, Mererani, Chekereni and Mawenzi Regional Hospital)

    Moshi, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.